ProCE Banner Activity

UNITY-CLL: Phase III Trial of Umbralisib + Ublituximab vs Obinutuzumab + Chlorambucil in Patients With CLL

Slideset Download
Conference Coverage
In the phase III UNITY-CLL trial, umbralisib + ublituximab demonstrated superior PFS benefit vs chlorambucil + obinutuzumab in both previously untreated and previously treated patients with CLL.

Released: December 18, 2020

Expiration: December 17, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology